Gardasil

Gardasil - most related articles:

- Gardasil approval delayed for use in women ages 27 - 45 - 6.9
- Gardasil HPV vaccine prevented genital lesions in men - 6.5
- Gardasil efficacious against HPV 16 infection - 6.5
- Gardasil approved to prevent anal cancer - 6.3
- Gardasil is eligible for UN immunization programs - 6.3
- Gardasil vaccine to prevent cervical cancer in India - 6
- Gardasil HPV vaccine reduces abnormal pap test results - 5.5

Gardasil articles

Gardasil approved to prevent anal cancer
The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.

Gardasil is eligible for UN immunization programs
GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck's cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL is the first cervical cancer vaccine to receive WHO pre-qualification.

Gardasil efficacious against HPV 16 infection
In a study of an extended follow up of 290 women naïve to HPV type 16, the HPV 16 component of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was efficacious against HPV 16 infection for an average of 8.5 years after administration.

Gardasil approval delayed for use in women ages 27 - 45
Merck & Co., Inc. announced that the U.S. Food and Drug Administration has issued a second complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] in women ages 27 though 45.

HPV vaccine's hypersensitivity reactions are rare
Hypersensitivity reactions to the quadrivalent HPV vaccine (4vHPV, Gardasil) are uncommon and most schoolgirls can tolerate subsequent doses, finds the first evaluation of the quadrivalent HPV vaccine published on bmj.com.

Gardasil HPV vaccine prevented genital lesions in men
GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26.

Gardasil vaccine to prevent cervical cancer in India
MSD Pharmaceuticals India announced the launch of GARDASIL Vaccine, India's first vaccine to help prevent Cervical Cancer caused by the HPV.

Gardasil HPV vaccine reduces abnormal pap test results
A significant drop in abnormal Pap test results happened after girls and women were given Gardasil vaccine to prevent cervical cancer, according to a researcher at the University of Alabama at Birmingham (UAB).

8 Gardasil articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
2.97